BiotechTube

LAS41003 + LAS189962 + LAS189961

Phase 2Completed
0 watching 0 views this week⚡ Active
47
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Eczema

Conditions

Eczema

Trial Timeline

Nov 1, 2009 → Jun 1, 2010

NCT ID
NCT01020994

About LAS41003 + LAS189962 + LAS189961

LAS41003 + LAS189962 + LAS189961 is a phase 2 stage product being developed by Almirall for Eczema. The current trial status is completed. This product is registered under clinical trial identifier NCT01020994. Target conditions include Eczema.

Hype Score Breakdown

Clinical
17
Activity
12
Company
5
Novelty
5
Community
5

Clinical Trials (2)

NCT IDPhaseStatus
NCT01102387Phase 2Completed
NCT01020994Phase 2Completed

Competing Products

20 competing products in Eczema

See all competitors
ProductCompanyStageHype Score
1% Colloidal Oatmeal BalmJohnson & JohnsonPre-clinical
23
Colloidal Oatmeal CreamJohnson & JohnsonPhase 3
77
Pimecrolimus cream 1%NovartisApproved
85
AbrocitinibPfizerPhase 3
76
Dupilumab + PlaceboSanofiPhase 2
51
Amlitelimab + PlaceboSanofiPhase 2
51
alitretinoin + PlaceboGSK plcPhase 3
76
DupilumabRegeneron PharmaceuticalsApproved
84
Adventan® (methylprednisolone aceponate 0,1%)BayerPhase 1
30
Ruxolitinib cream + VehicleIncytePhase 3
74
Ruxolitinib cream + VehicleIncytePhase 2
49
Ruxolitinib cream + VehicleIncytePhase 3
74
ARQ-151 Cream 0.15% or ARQ-151 Cream 0.05%Arcutis BiotherapeuticsPhase 3
72
Roflumilast Cream + Vehicle creamArcutis BiotherapeuticsPhase 3
72
ARQ-151 cream 0.05%Arcutis BiotherapeuticsPhase 2
47
Roflumilast Cream 0.05% + Vehicle CreamArcutis BiotherapeuticsPhase 3
72
Roflumilast Cream 0.15% + Vehicle CreamArcutis BiotherapeuticsPhase 3
72
ARQ-151 cream 0.15% + ARQ-151 cream 0.05%Arcutis BiotherapeuticsPhase 1
28
ARQ-252 cream 0.3% + ARQ-252 cream 0.1% + ARQ-252 Vehicle CreamArcutis BiotherapeuticsPhase 1/2
36
LAS 41002 + ActiveAlmirallPhase 2
47

Other Products from Almirall

TildrakizumabApproved
80
Tiotropium + AclidiniumApproved
80
Dimethyl fumarate (DMF) standard scheme + Dimethyl fumarate (DMF) simplified scheme + TildrakizumabApproved
80
Pidotimod + PlaceboApproved
80
Tirbanibulin (Klisyri®) 10 mg/g ointment + Diclofenac Sodium 3% GelApproved
80